Systematic Financial Management LP Sells 165 Shares of Taro Pharmaceutical Industries Ltd. (TARO)

Share on StockTwits

Systematic Financial Management LP lowered its position in shares of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) by 1.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 12,435 shares of the company’s stock after selling 165 shares during the quarter. Systematic Financial Management LP’s holdings in Taro Pharmaceutical Industries were worth $1,344,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Jane Street Group LLC bought a new position in shares of Taro Pharmaceutical Industries during the fourth quarter valued at $239,000. Bank of New York Mellon Corp increased its holdings in shares of Taro Pharmaceutical Industries by 86.5% during the fourth quarter. Bank of New York Mellon Corp now owns 57,216 shares of the company’s stock valued at $4,843,000 after acquiring an additional 26,540 shares in the last quarter. Summit Global Investments bought a new position in shares of Taro Pharmaceutical Industries during the fourth quarter valued at $609,000. Acadian Asset Management LLC increased its holdings in shares of Taro Pharmaceutical Industries by 9.7% during the fourth quarter. Acadian Asset Management LLC now owns 308,588 shares of the company’s stock valued at $26,117,000 after acquiring an additional 27,175 shares in the last quarter. Finally, Quantamental Technologies LLC bought a new position in shares of Taro Pharmaceutical Industries during the fourth quarter valued at $110,000. 10.16% of the stock is owned by institutional investors and hedge funds.

TARO has been the subject of several research analyst reports. Zacks Investment Research upgraded Taro Pharmaceutical Industries from a “sell” rating to a “hold” rating and set a $114.00 price objective for the company in a report on Friday, February 8th. TheStreet upgraded Taro Pharmaceutical Industries from a “c” rating to a “b-” rating in a report on Friday, February 15th.

NYSE TARO traded up $0.06 during trading hours on Friday, hitting $101.40. The company’s stock had a trading volume of 2,529 shares, compared to its average volume of 58,916. Taro Pharmaceutical Industries Ltd. has a 12 month low of $76.93 and a 12 month high of $121.23. The company has a market capitalization of $4.02 billion, a price-to-earnings ratio of 16.36 and a beta of 0.51.

TRADEMARK VIOLATION NOTICE: “Systematic Financial Management LP Sells 165 Shares of Taro Pharmaceutical Industries Ltd. (TARO)” was first reported by Equities Focus and is the sole property of of Equities Focus. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.equitiesfocus.com/2019/05/17/systematic-financial-management-lp-sells-165-shares-of-taro-pharmaceutical-industries-ltd-taro.html.

Taro Pharmaceutical Industries Company Profile

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.

See Also: Why is the Consumer Price Index (CPI) important?

Want to see what other hedge funds are holding TARO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Taro Pharmaceutical Industries Ltd. (NYSE:TARO).

Institutional Ownership by Quarter for Taro Pharmaceutical Industries (NYSE:TARO)

Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.